Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
221.32
-1.19 (-0.53%)
At close: May 8, 2026, 4:00 PM EDT
221.25
-0.07 (-0.03%)
After-hours: May 8, 2026, 7:59 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $24.06B in the quarter ending March 31, 2026, with 9.91% growth. This brings the company's revenue in the last twelve months to $96.36B, up 7.87% year-over-year. In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth.
Revenue (ttm)
$96.36B
Revenue Growth
+7.87%
P/S Ratio
5.53
Revenue / Employee
$697,265
Employees
138,200
Market Cap
532.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 31, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 31, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 31, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 31, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 31, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 72.25B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
JNJ News
- 3 days ago - This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J - Barrons
- 3 days ago - Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission - PRNewsWire
- 5 days ago - CVS to drop J&J's Stelara from its main formularies - Reuters
- 5 days ago - Johnson & Johnson announces results from Phase 3 FUZION study of tremfya - TheFly
- 5 days ago - Johnson & Johnson announces Phase 2b data from JNJ-4804 studies - TheFly
- 5 days ago - Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease - PRNewsWire
- 5 days ago - Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease - PRNewsWire
- 5 days ago - Johnson & Johnson announces study of OTTAVA System met primary endpoints - TheFly